Galmed Pharmaceuticals(GLMD) Prnewswire·2025-04-02 20:10Company Overview - Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases, and GI oncological indications [1][3] - The company is developing Aramchol for oncological indications outside of liver disease and is actively pursuing opportunities to expand its product pipeline [3] Financial Reporting - Galmed has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission [1] - The report is accessible on the SEC's website and Galmed's Investor Relations website [2] Strategic Focus - The company aims to diversify its product pipeline specifically targeting cardiometabolic indications and other innovative product candidates [3]